AstraZeneca_NNP Annual_JJ Report_NNP and_CC 84_CD Form_NN 20-F_JJ Information_NN 2005_CD CONSOLIDATED_NNP INCOME_NNP STATEMENT_NNP FOR_IN THE_DT YEAR_NN ENDED_VBD 31_CD DECEMBER_NNP 2005 2004 2003_CD Notes_NNP $_$ m_CD $_$ m_CD $_$ m_CD Sales_NNS 23,950_CD 21,426_CD 18,849_CD Cost_NN of_IN sales_NNS 5,356_CD 5,193_CD 4,463_CD Distribution_NN costs_NNS 211 177 162_CD Research_NNP and_CC development_NN 3,379_CD 3,467_CD 3,012_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ costs_NNS 8,695_CD 8,268_CD 7,393_CD Other_JJ operating_NN income_NN 1_CD 193 226 188_CD Operating_NN profit_NN 1_CD 6,502_CD 4,547_CD 4,007_CD Profit_NN on_IN sale_NN of_IN interest_NN in_IN joint_JJ venture_NN 2_CD 219_CD Finance_NNP income_NN 3_CD 665 532 381_CD Finance_NNP expense_NN 3_CD 500 454 311_CD Profit_NN before_IN tax_NN 6,667_CD 4,844_CD 4,077_CD Taxation_NNP 4_CD 1,943_CD 1,161_CD 1,033_CD Profit_NN for_IN the_DT period_NN 4,724_CD 3,683_CD 3,044_CD Attributable_JJ to_TO :_: Equity_NNP holders_NNS of_IN the_DT Company_NN 4,706_CD 3,664_CD 3,022_CD Minority_NNP interests_NNS 20_CD 18_CD 19_CD 22_CD Basic_JJ earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP 5_CD $_$ 2.91_CD $_$ 2.18_CD $_$ 1.77_CD Diluted_VBN earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP 5_CD $_$ 2.91_CD $_$ 2.18_CD $_$ 1.77_CD Weighted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 5_CD 1,617_CD 1,673_CD 1,709_CD Diluted_VBN average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS 5_CD 1,618_CD 1,675_CD 1,712_CD Dividends_NNS declared_VBD and_CC paid_VBD in_IN the_DT period_NN 21_CD 1,676_CD 1,408_CD 1,244_CD All_DT activities_NNS were_VBD in_IN respect_NN of_IN continuing_VBG operations_NNS ._.
CONSOLIDATED_JJ STATEMENT_NN OF_IN RECOGNISED_NNP INCOME_NNP AND_CC EXPENSE_NNP FOR_IN THE_DT YEAR_NN ENDED_VBD 31_CD DECEMBER_NNP 2005 2004 2003_CD Notes_NNP $_$ m_CD $_$ m_CD $_$ m_CD Profit_NN for_IN the_DT period_NN 4,724_CD 3,683_CD 3,044_CD Foreign_JJ exchange_NN adjustments_NNS on_IN consolidation_NN 18_CD 1,052_CD 744_CD 1,267_CD Available_JJ for_IN sale_NN losses_NNS gains_VBZ taken_VBN to_TO equity_NN 18_CD 10_CD 31_CD 1_CD Actuarial_JJ loss_NN for_IN the_DT period_NN 18 35 179 240_CD Tax_NNP on_IN items_NNS taken_VBN directly_RB to_TO reserves_NNS 4_CD ,_, 18 25 416 139_CD 1,122_CD 1,012_CD 1,167_CD Total_JJ recognized_VBN income_NN and_CC expense_NN for_IN the_DT period_NN 3,602_CD 4,695_CD 4,211_CD Attributable_JJ to_TO :_: Equity_NNP holders_NNS of_IN the_DT Company_NN 3,595_CD 4,690_CD 4,186_CD Minority_NNP interests_NNS 7_CD 525_CD Tax_NNP on_IN items_NNS taken_VBN directly_RB to_TO reserves_NNS in_IN 2004_CD includes_VBZ a_DT credit_NN of_IN $_$ 357m_CD in_IN respect_NN of_IN foreign_JJ exchange_NN losses_NNS in_IN 2000_CD Note_NN 4_CD ._.
$_$ m_JJ means_NNS millions_NNS of_IN US_NNP dollars_NNS
